Phaseline

Companies › Senhwa Biosciences

Senhwa Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CX-5461
POLR2A/POLR1A inhibitor; transcription inhibitor targeting ribosomal RNA synthesis
POLR2A, POLR1APhase 1Advanced Solid TumorMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04890613CX-5461Phase 1Advanced Solid TumorOncologyMar 2027

Targets

POLR2A (1) POLR1A (1)

Companies with the same targets

Henan Genuine Biotech Luye Pharma Group GSK Jiangsu Hansoh Pharmaceutical Gilead Sciences Merck & Co. (MSD)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.